ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 70. Lang RM, Badano LP, Tsang W, Adams DH, Agricola E, Buck T, et al. EAE/ ASE recommendations for image acquisition and display using three- dimensional echocardiography. J AmSoc Echocardiogr. 2012;25(1):3–46. 71. AghaSA,KalogeropoulosAP,ShihJ,GeorgiopoulouVV,GiamouzisG,Anarado P, et al. Echocardiography and riskprediction in advanced heart failure: incremental value over clinicalmarkers. J Card Fail. 2009;15(7):586–9. 72. Platz E, Lewis EF, Uno H, Peck J, Pivetta E, Merz AA, et al. Solomon. Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients.Eur Heart J. 2016;37(15):1244-51. 73. Andersen OS, Smith OA, Dokainish H, Abudiab MM, Schutt RC, Kumar A, et al. Estimating left ventricular filling pressure by echocardiography. JACC. 2017;69(15):1937-48. 74. Nagueh SF. Non-invasive assessment of left ventricular filling pressure. Eur J Heart failure 2018;20(1):38-48 75. Kongbundansuk S, Hundley G. Noninvasive imaging of cardiovascular injury related to the treatment of cancer. J Am Coll Cardiol Img. 2014;7(8):824–38. 76. Gonzalez JA, Kramer CM. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. Curr Heart Fail Rep. 2015;12(4):276–28 77. Kilner PJ, Geva T, Kaemmerer H, Trindade PT, Schwitter J, Webb GD. Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology.Eur Heart J. 2010;31(7):794–805. 78. Valle-Munoz A, Estornell-Erill J, Soriano-Navarro CJ, Nadal- Barange M, Martinez-Alzamora N, Pomar-Domingo F, et al. Late gadoliniumenhancement-cardiovascular magnetic resonance identifies coronaryartery disease as the aetiology of left ventricular dysfunction in acutenew-onset congestive heart failure. Eur J Echocardiogr. 2009;10(8):968–74. 79. Yoshida A, Ishibashi-Ueda H, Yamada N, Kanzaki H, Hasegawa T, Takahama H, et al. Direct comparison of the diagnostic capabilityof cardiac magnetic resonance and endomyocardial biopsy in patients with heartfailure. Eur J Heart Fail. 2013;15(2):166–175. 80. Choudhary P, Hsu CJ, Grieve S, Smillie C, Singarayar S, Semsarian C, et al. Improving the diagnosis of LV non-compaction with cardiac magnetic resonance imaging. Int J Cardiol. 2015 Feb 15;181:430-6. 81. Torreão JA, Ianni BM, Mady C, Naia E, Rassi CH, Nomura C, et al. Myocardial tissue characterization in Chagas' heart disease by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2015 Nov 18;17:97. 82. Haneder S, Kucharczyk W, Schoenberg SO, Michaely HJ. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis. Top Magn Reson Imaging. 2015;24(1):57–65. 83. Beller GA, Heede RC. SPECT imaging for detecting coronary artery disease anddetermining prognosis by noninvasive assessment of myocardial perfusion andmyocardial viability. J CardiovascTransl Res. 2011;4(4):416–424. 84. AtchleyAE,KitzmanDW,WhellanDJ, IskandrianAE,EllisSJ,PagnanelliRA, et al. Myocardial perfusion,function, and dyssynchrony in patients with heart failure: baseline resultsfrom the single-photon emission computed tomography imaging ancillarystudy of the Heart Failure and A Controlled Trial Investigating Outcomesof Exercise TraiNing (HF-ACTION) Trial. Am Heart. J 2009;158(4 Suppl):S53–6. 85. Soman P, Lahiri A, Mieres JH, Calnon DA, Wolinsky D, Beller GA, et al. Etiology and pathophysiology ofnew-onset heart failure: evaluation by myocardial perfusion imaging. J Nucl Cardiol. 2009;16(1):82–91. 86. BonowRO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival inischemic left ventricular dysfunction. N Engl J Med. 2011;364(17):1617–25. 87. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, FreemanM, et al. F-18-fluorodeoxyglucose positron emission tomographyimaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am CollCardiol 2007;50(20):2002–12. 88. Peix A, Mesquita CT, PaezD, Pereira CC, Felix R, Gutierrez C, et al. Nuclear medicine in themanagement of patients with heart failure:guidance from an expert panel of the International Atomic Energy Agency(IAEA). Nucl Med Commun. 2014;35(8):818–23. 89. Butler J. The emerging role of multi-detector computed tomography inheart failure. J Card Fail. 2007;13(3):215–26. 90. Rizzello V, Poldermans D, Biagini E, Schinkel AF, Boersma E, Boccanelli A, et al. Prognosis of patients withischaemic cardiomyopathy after coronary revascularisation: relation toviability and improvement in left ventricular ejection fraction. Heart. 2009;95(15):1273–7. 91. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am CollCardiol 2002;39(7):1151–8. 92. Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 1997;96(3):793–800. 93. Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography predicts long-termsurvival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol. 1999;33(7):1848–54. 94. Kwon DH, Halley CM, Carrigan TP, Zysek V, Popovic ZB, Setser R, . Extent of left ventricular scar predicts outcomes in ischemic cardiomyopathy patients with significantly reduced systolic function: a delayed hyperenhancement cardiac magnetic resonance study. JACC Cardiovasc Imaging 2009;2(1):34–44. 95. BonowRO, Castelvecchio S, Panza JA, BermanDS, Velazquez EJ, Michler RE, et al. Severity of remodeling, myocardial viability, and survival in ischemic LV dysfunction after surgical revascularization. JACCCardiovasc Imaging 2015;8(10):1121–9. 96. Arena R, Myers J, Abella J, Pinkstaff S, Brubaker P, KitzmanD, et al. Defining the Optimal PrognosticWindow for Cardiopulmonary Exercise Testing in Patients with Heart Failure. Circ Heart Fail. 2010;3(3):405–11. 97. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of Peak Exercise Oxygen Consumption for Optimal Timing of Cardiac Transplantation in Ambulatory Patients With Heart Failure. Circulation. 1991;83(3):778-86. 98. Corra U, Piepoli MF, Adamopoulos S, Agostoni P, Coats AJ, Conraads V, et al. Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role: a position paper from the committee on exercise physiology and training of the heart failureassociation of the ESC. Eur J Heart Fail 2014;16: 929–41. 99. Maisel A, Mueller C, Adams K, Anker SD, Aspromont N, Cleland JGF, et al. State of the art: using natriuretic peptides in clinical practice. Eur J Heart Fail. 2008;10(9):824-39. 100. Felker GM, AnstromKJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, et al. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2017;318(8):713-20. 101. Packer M, McMurray JJV, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61. 102. Kociol RD, Pang PS, GheorghiadeM, FonarowGC, O’Connor CM, Felker GM. Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56(14):1071-8. 519